Cellu Tissue — Merger or Acquisition (September 2010)
14 slides from Cellu Tissue's merger presentation, Sep 16, 2010
Slide 1: Schedule 14A Proxy Statement Cover - Cellu Tissue Holdings
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy
Slide 2: Fee paid previously with preliminary materials
¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule
Slide 3: Cellu Tissue Acquisition Conference Call
Clearwater Paper Corporation Cellu Tissue Acquisition Conference Call September 16, 2010
Slide 4: Forward-Looking Statements
Forward-Looking Statements Our disclosure and analysis in this presentation contains, in addition to historical information, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected accretion to earnings, t
Slide 5: Transaction Overview
Transaction Overview • Clearwater Paper has agreed to acquire Cellu Tissue Holdings, Inc. • Total cash consideration of approximately $502 million • Price per Cellu Tissue share is $12.00 • Approximately $255 million of Cellu Tissue existing net debt to be retired or assumed • Transaction to be fina
Slide 6: Strategic & Financial Rationale
Strategic & Financial Rationale • Acquisition supports strategy to grow the size and scope of Consumer Products segment • Premier national tissue manufacturer and converter of private label tissue products • Combined annual company revenues of approximately $1.9 billion • Complementary geographical
Slide 7: Historical Pro Forma Financial Overview
Historical Pro Forma Financial Overview Last Twelve Months (LTM) US $ in millions 1,3 Pro Forma LTM Clearwater Combined Paper Cellu Tissue (Excluding Synergies) , Net Sales $1,320.9¹ $524.5³ $1,845.4¹ ³ 4 Adjusted EBITDA $165.3² $73.2 $238.5² 4 Adjusted EBITDA Margin 12.5% 14.0% 12.9% Note: Adjusted
Slide 8: Pro Forma Revenue Mix Change
Pro Forma Revenue Mix Change Last Twelve Months (LTM) 1,2 Percentage of sales from Consumer Products segment increases significantly with Cellu Tissue acquisition. 1 Includes the results of Clearwater Paper for the last twelve months ended June 30, 2010. 2 Includes the results of Cellu Tissue for th
Slide 9: Strong Geographic Fit
Strong Geographic Fit Clearwater Complementary Geographic Asset Bases Cellu Tissue Spokane, WA Ladysmith, WI Corporate Headquarters Capacity: 55,000 tons Neenah, WI Capacity: 85,000 tons Menominee, MI Lewiston, ID Capacity: 32,000 tons Converting Capacity: 102,000 tons Lewiston, ID (Tissue) St. Cath
Slide 10: Customer Relationship Expansion
Customer Relationship Expansion Consumer Products Segment Cellu Tissue Customer Opportunity Add National Grocery Customers National Broad Add Regional Grocery Grocery Customer Customers Channel Base Add Value Retailers (mass, disc, dollar) 7
Slide 11: Conservative Pro Forma Capitalization
Conservative Pro Forma Capitalization ($ in millions) Clearwater Cellu Tissue 6/30/2010 5/27/2010 Pro Forma5 Cash and Short-Term Investments $333.0 $3.2 $ 126.5 Clearwater Revolving Credit Facility 1 - - - 2 Clearwater Senior Unsecured Notes due 2016 148.4 - 148.4 Cellu Tissue Revolving Credit Facil
Slide 12: Thank you.
yy CLEARWATER PAPER Thank you.
Slide 13: Appendix A: US GAAP Reconciliation
Appendix A: US GAAP Reconciliation 10
Slide 14: Reconciliation of Non-GAAP to GAAP: EBITDA
Reconciliation of Non-GAAP to GAAP: EBITDA U.S. $ in millions Clearwater Cellu Pro Forma 1 3 1,3 Paper Tissue LTM Net Earnings $114.3 $0.1 $114.4 Income Tax Provision 80.7 2.8 83.5 Interest Expense, Net 16.9 40.6 57.5 Earnings Before Interest and $211.9 $43.5 $255.4 Income Taxes Depreciation & Amort
Cellu Tissue Holdings — Merger or Acquisition (September 2010) on 6ix